Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

Journal of Immunology

Volumn 164, Issue 9, 2000, Pages 4968-4978

  Allen, Todd M ^a   Vogel, Thorsten U ^a   Fuller, Deborah H ^b   Mothé, Bianca R ^a   Steffen, Susan ^a   Boyson, Jon E ^a,c   Shipley, Tim ^b   Fuller, Jim ^b   Hanke, Tomas ^d   Sette, Alessandro ^e   Altman, John D ^f   Moss, Bernard ^g   McMichael, Andrew J ^e   Watkins, David I ^a,h  

^a UNIVERSITY OF WISCONSIN   (United States)

^b Process Formulation and Analytical Laboratories   (United States)

^c HARVARD UNIVERSITY   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e Epimmune   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS VACCINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ASSAY; HELPER CELL; IMMUNE RESPONSE; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS REPLICATION;

ANKARA;

EID: 18144441678     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.9.4968     Document Type: Article

References (74)

1. Gold, D. 1999. IAVI Report. International AIDS Vaccine Initiative, New York.
2. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, et al. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295.
3. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Z. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.
4. Borrow, P., H. Lewicki, X. P. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. A. Oldstone, et al. 1997. Antiviral pressure exerted By HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3:205.
5. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94:1890.
6. Koenig, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, C. Carter, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330.
7. Haas, G., U. Plikat, P. Debre, M. Lucchiari, C. Katlama, Y. Dudoit, O. Bonduelle, M. Bauer, H. G. Ihlenfeldt, G. Jung, et al. 1996. Dynamics of viral variants in HIV-I nef and specific cytotoxic T lymphocytes in vivo. J. Immunol. 157:4212.
8. Wolinsky, S. M., B. T. Korber, A. U. Neumann, M. Daniels, K. J. Kunstman, A. J. Whetsell, M. R. Furtado, Y. Cao, D. D. Ho, and J. T. Safrit. 1996. Adaptive evolution of human immunodeficiency virus-type I during the natural course of infection. Science 272:537.
9. Soudeyns, H., S. Paolucci, C. Chappey, M. B. Daucher, C. Graziosi, M. Vaccarezza, O. J. Cohen, A. S. Fauci, and G. Pantaleo. 1999. Selective pressure exerted by immunodominant HIV-1-specific cytotoxic T lymphocyte responses during primary infection drives genetic variation restricted to the cognate epitope. Eur. J. Immunol. 29:3629.
10. Evans, D. T., D. H. O'Connor, P. Jing, D. J. L., J. Sydney, J. da Silva, T. M. Allen, H. Norton, J. E. Venham, R. A. Rudersdorf, C. D. Pauza, et al. 1999. Virus-specific CTL responses select for amino acid variation in SIV Env and Nef. Nat. Med. 5:1270.
11. Brodie, S. J., D. A. Lewinsohn, B. K. Patterson, D. Jiyamapa, J. Krieger, L. Corey, P. D. Greenberg, and S. R. Riddell. 1999. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med. 5:34.
12. + lymphocytes. Science 283:857.
13. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:991.
14. Matano, T., R. Shibata, C. Siemon, M. Connors, H. C. Lane, and M. A. Martin. 1998. Administration of an anti-CD8 monolonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72:164.
15. Ishioka, G. Y., J. Fikes, G. Hermanson, B. Livingston, C. Crimi, M. S. Qin, M. F. del Guercio, C. Oseroff, C. Dahlberg, J. Alexander, et al. 1999. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. 162:3915.
16. Oukka, M., J. C. Manuguerra, N. Livaditis, S. Tourdot, N. Riche, I. Vergnon, P. Cordopatis, and K. Kosmatopoulos. 1996. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 157:3039.
17. Tourdot, S., M. Oukka, J. C. Manuguerra, V. Magafa, I. Vergnon, N. Riche, M. Bruley-Rosset, P. Cordopatis, and K. Kosmatopoulos. 1997. Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination. J. Immunol. 159:2391.
18. McMichael, A. J., and R. E. Phillips. 1997. Escape of human immunodeficiency virus from immune control. Annu. Rev. Immunol. 15:271.
19. Couillin, I., B. Culmann-Penciolelli, E. Gomard, J. Choppin, J. P. Levy, J. G. Guillet, and S. Saragosti. 1994. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J. Exp. Med. 180:1129.
20. Cooper, S., A. E. Erickson, E. J. Adams, J. Kansopon, A. J. Weiner, D. Y. Chien, M. Houghton, P. Parham, and C. M. Walker. 1999. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439.
21. Missale, G., R. Bertoni, V. Lamonaca, A. Valli, M. Massari, C. Mori, M. G. Rumi, M. Houghton, F. Fiaccadori, and C. Ferrari. 1996. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J. Clin. Invest. 98:706.
22. Crook, T., J. P. Morgenstem, L. Crawford, and L. Banks. 1989. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMKO J. 8:513.
23. Hawley-Nelson, P., K. H. Vousden, N. L. Hubbert, D. R. Lowy, and J. T. Schiller, 1989. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 8:3905.
24. Lodmell, D. L, N. B. Ray, M. J. Parnell, L. C. Ewalt, C. A. Hanlon, J. H. Shaddock, D. S. Sanderlin, and C. E. Rupprecht. 1998. DNA immunization protects nonhuman primates against rabies virus. Nat. Med. 4:949.
25. Wang, R. B., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. P. Charoenvit, T. R. Jones, P. Hobart, M. Margalit, J. Ng, et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282:476.
26. Ulmer, J. B., J. J. Donnelly, S. E. Parker, G. H. Rhodes, P. E. Feigner, V. J. Dwarki, S. H. Gromkowski, R. R. Deck, C. M. De Win, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745.
27. Donnelly, J. J., A. Friedman, D. Martinez, D. E. Montgomery, J. W. Shiver, S. L. Motzel, J. B. Ulmer, and M. A. Liu. 1995. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1:583.
28. Fuller, D. H., M. Murphey-Corb, J. Clements, S. Barnett, and J. R. Haynes. 1996. Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J. Med. Primatol. 25:236.
29. Boyer, J. D., B. Wang, K. E. Ugen, M. Agadjanyan, A. Javadian, P. Frost, K. Dang, R. A. Carrano, R. Ciccarelli, L. Coney, et al. 1996. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J. Med. Primatol. 25:242.
30. Shiver, J. W., M. E. Davies, Y. Yasutomi, H. C. Perry, D. C. Freed, N. E. Letvin, and M. A. Liu. 1997. Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 15:884.
31. Boyer, J. D., K. E. Ugen, B. Wang, M. Agadjanyan, E. Gilbert, M. L. Bagarazzi, M. Chattergoon, P. Frost, A. Javadian, W. V. Williams, et al. 1997. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med. 3:526.
32. Lu, S., J. Arthos, D. C. Montefiori, Y. Yasutomi, K. Manson, F. Mustafa, E. Johnson, J. C. Santoro, J. Wissink, J. I. Mullins, et al. 1996. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978.
33. Yasutomi, Y., H. L. Robinson, S. Lu, F. Mustafa, C. Lekutis, J. Arthos, J. I. Mullins, G. Voss, K. Manson, M. Wyand, et al. 1996. Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus monkeys. J. Virol. 70:678.
34. Kent, S. J., A. Zhao, S. J. Best, J. D. Chandler, D. B. Boyle, and I. A. Ramshaw, 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72:10180.
35. Sedegah, M., T. R. Jones, M. Kaur, R. Hedstrom, P. Hobart, J. A. Tine, and S. E. Hoffman, 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95:7648.
36. Letvin, N. E., D. C. Montefiori, Y. Yasutomi, H. C. Perry, M. E. Davies, C. Lekutis, M. Alroy, D. C. Freed, C. I. Lord, E. K. Handt, et al. 1997. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 94:9378.
37. Hanke, T., T. J. Blanchard, J. Schneider, C. M. Hannan, M. Becker, S. C. Gilbert, A. V. Hill, G. L. Smith, and A. McMichael. 1998. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439.
38. Hanke, T., and A. McMichael. 1999. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol. Lett. 66:177.
39. Robinson, H. L., D. C. Montefiori, R. P. Johnson, K. H. Manson, M. L. Kalish, J. D. Lifson, T. A. Rizvi, A. Lu, S. Hu, G. P. Mazzara, et al. 1999. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:526.
40. Sutter, G., L. S. Wyatt, P. L. Foley, J. R. Bennink, and B. Moss. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12:1032.
41. Hirsch, V. M., T. R. Fuerst, G. Sutter, M. W. Carroll, L. C. Yang, S. Goldstein, M. Piatak, Jr., W. R. Elkins, W. G. Alvord, D. C. Montefiori, et al. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70:3741.
42. Seth, A., I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin. 1998. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer. Proc. Natl. Acad. Sci. USA 95:10112.
43. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 72:8264.
44. Hanke, T., T. J. Blanchard, J. Schneider, G. S. Ogg, R. Tan, M. Becker, S. C. Gilbert, A. V. Hill, G. L. Smith, and A. McMichael. 1998. Immunogenicitics of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J. Gen. Virol. 79:83.
45. Miller, M. D., H. Yamamoto, A. L. Hughes, D. I. Watkins, and N. L. Letvin. 1991. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147:320.
46. Allen, T. M., J. Sidney, M. F. Delguercio, R. L. Glickman, G. L. Lensmeyer, D. A. Wiebe, R. Demars, C. D. Pauza, R. P. Johnson, A. Sette, et al. 1998. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160:6062.
47. Knapp, L. A., E. Lehmann, M. S. Piekarczyk, J. A. Urvater, and D. I. Watkins. 1997. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing. Tissue Antigens 50:657.
48. Hanke, T., J. Schneider, S. C. Gilbert, A. V. S. Hill, and A. McMichael. 1998. DNA multi-CTL epitope vaccines for HIV and plasmodium falciparum-immunogenicity in mice. Vaccine 16:426.
49. Chen, Z. W., L. Shen, M. D. Miller, S. H. Ghim, A. L. Hughes, and N. L. Letvin. 1992. Cytotoxic T lymphocytes do not appear to select for mutations in an immunodominant epitope of simian immunodeficiency virus gag. J. Immunol. 149: 4060.
50. Kuroda, M. J., J. E. Schmitz, D. H. Barouch, A. Craiu, T. M. Allen, A. Sette, D. I. Watkins, M. A. Forman, and N. L. Letvin. 1998. Analysis of gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I peptide complex. J. Exp. Med. 187:1373.
51. Hanke, T., T. J. Blanchard, V. C. Neumann, J. E. Boyson, P. Sweeney, T. M. Allen, D. I. Watkins, G. L. Smith, and A. McMichael. 1999. Effective induction of SIV-specific CTL in macaques using a DNA prime-MVA boost vaccination regimen. J. Virol. 73:7524.
52. Altman, J. D., P. A. H. Moss, P. J. R. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94.
53. Klinman, D. M. 1994. ELISPOT assay to detect cytokine-secreting murine and human cells. Curr. Protocols Immunol. 6.19:1.
54. Fomsgaard, A., H. V. Nielsen, K. Bryder, C. Nielsen, R. Machuca, L. Bruun, J. Hansen, and S. Buus. 1998. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen. Scand. J. Immunol. 47:289.
55. Ulrich, R., M. Nassal, H. Meisel, and D. H. Kruger. 1998. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res. 50:141.
56. Schodel, F., D. Peterson, J. Hughes, R. Wirtz, and D. Milich. 1996. Hybrid hepatilis B virus core antigen as a vaccine carrier moiety. I. Presentation of foreign epitopes. J. Biotechnol. 44:91.
57. Schodel, F., D. Peterson, and D. Milich. 1996. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety. Intervirology 39:104.
58. Fuller, D. H., M. M. Corb, S. Barnett, K. Steimer, and J. R. Haynes. 1997. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 15:924.
59. van der Meide, P. H., A. M. Joosten, P. Hermans, T. C. Kloosterman, T. Olsson, and M. C. de Labie. 1991. Assessment of the inhibitory effect of immunosuppressive agents on rat T cell interferon-γ production using an ELISPOT assay. J. Immunol. Methods 144:203.
60. Larsson, M., X. Jin, B. Ramratnam, G. S. Ogg, J. Engelmayer, M. A. Demoitie, A. J. McMichael, W. I. Cox, R. M. Steinman, D. Nixon, et al. 1999. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Polspecific CDS T cells in HIV-1-positive individuals. AIDS 13:767.
61. Lalvani, A., and A. V. S. Hill. 1998. Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design. Clin. Sci. 95:531.
62. + T-cell responses. Immunol. Lett. 66:77.
63. Couedel-Courteille, A., R. Le Grand, M. Tulliez, I. C. Guillet, and A. Venet. 1997. Direct ex vivo simian immunodeficiency virus (SIV)-specific cytotoxic activity detected from small intestine intraepithelial lymphocytes of SIV-infected macaques at an advanced stage of infection. J. Virol. 71:1052.
64. Pantaleo, G., C. Graziosi, J. F. Demarest, L. Butini, M. Montroni, C. H. Fox, J. M. Orenslein, D. P. Kotler, and A. S. Fauci. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355.
65. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooley. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328:345.
66. Kuroda, M. J., J. E. Schmitz, W. A. Charini, C. E. Nickerson, M. A. Lifton, C. I. Lord, M. A. Forman, and N. L. Letvin. 1999. Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J. Immunol. 162:5127.
67. Murali-Krishna, K., J. D. Altman, M. Suresh, D. J. Sourdive, A. J. Zajac, J. D. Miller, J. Slansky, and R. Ahmed. 1998. Counting antigen-specific CD8 T cells: a recvaluation of bystander activation during viral infection. Immunity 8:177.
68. + memory T cells. J. Exp. Med. 186:859.
69. McMichael, A. J., and C. A. O'Callaghan. 1998. A new look at T cells. J. Exp. Med. 187:1367.
70. + T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J. Virol. 70:4941.
71. Hulskotte, E. G., A. M. Geretti, K. H. Siebelink, G. van Amerongen, M. P. Cranage, E. W. Rud, S. G. Norley, P. de Vries, and A. D. Osterhaus. 1995. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J. Virol. 69:6289.
72. Egan, M. A., M. J. Kuroda, J. E. Schmitz, W. A. Charini, C. I. Lord, M. A. Forman, and N. L. Letvin. 1999. Use of major hislocompatibility complex class I/peptide/β2 M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys. J. Virol. 73:5466.
73. Whalen, J. A., P. R. Dunbar, D. A. Price, M. A. Purbhoo, F. Lechner, G. S. Ogg, G. Griffiths, R. E. Phillips, V. Cerundolo, and A. K. Sewell. 1999. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J. Immunol. 163:4342.
74. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:397.